Week in Review: ChinaBio® at China Showcase: The Golden Age for China Life Science Investing

ChinaBio®: Record Investing Levels Again in 2021; How Do Investors Adjust for 2022? In 2021, China Life Science Investing hit new all-time highs, said ChinaBio's Greg Scott in a year-end wrap-up, climbing 55% higher than last year's record levels; How do investors adjust to the Golden Age of China Life Science funding, an ecosystem that has been fully discovered? A China Showcase Panel discussed their plans;  Deals and Financings   Shanghai Junshi Bio reported its  US  partner, Coherus BioSciences, will exercise an option to in-license US-Canada rights for Junshi’s TIGIT antibody in a $290 million deal; Thousand Oaks Biopharma, headquartered in  Nantong , completed a $235 million Series D financing to expand its biologic CDMO operations; Sana , a Seattle biotech creating engineered cells as medicines, acquired rights to a BCMA CAR construct from IASO and Innovent in a $204 million agreement; Shanghai ZhenGe Biotech completed a $100 million C Round to strengthen its biologic drug CDMO services; Shanghai Fosun Pharma will collaborate with Insilico, a Hong Kong AI drug discovery company, to discover candidates for four targets; Accuredit Therapeutics ( Suzhou ) formed a JV with N1 Life of San Jose, CA to advance both companies' gene editing therapies toward clinical translation;  Trials and Approvals   CARsgen Therapeutics, a  Shanghai  CAR-T-company, was granted Regenerative Medicine Advanced Therapy designation in the  US  for a CAR T-cell product aimed at Claudin18.2-positive gastric cancers.  Stock Symbols: (HK: 1877; SHA: 688180) (NSDQ: SANA ) (HK: 01801) (SHA: 600196; HK: 02196) (HK: 2171) Share this with colleagues: // //